GIP-A

OTHER4 trials

Sponsors

University Hospital, Gentofte, Copenhagen, University of Copenhagen

Conditions

Acromegaly Due to Pituitary AdenomaGlucose MetabolismGlucose Metabolism Disorders

Unknown Phase

GIP Receptor Antagonist Studies in Humans

CompletedNCT02747472

University Hospital, Gentofte, CopenhagenGlucose Metabolism

Start: 2016-04-30End: 2016-07-31Updated: 2017-04-27

Delinieation of GIP's Effects During a Meal in Humans Using GIP Receptor Antagonisation (GA-4)

CompletedNCT03013296

University Hospital, Gentofte, CopenhagenGlucose Metabolism Disorders

Start: 2016-10-31End: 2018-09-30Updated: 2019-06-04

Inhibition of the Endogenous GIP Response With a GIP Receptor Antagonist

CompletedNCT03133741

University Hospital, Gentofte, CopenhagenGlucose Metabolism Disorders

Start: 2017-03-01End: 2017-07-01Updated: 2017-11-01

Modulating the GIP System in Patients With Acromegaly Due to a Pituitary Tumor

CompletedNCT03807076

University of CopenhagenAcromegaly Due to Pituitary Adenoma

Start: 2019-08-13End: 2023-11-28Updated: 2023-11-29

Related Papers

GIP(3-30)NH<sub>2</sub> is an efficacious GIP receptor antagonist in humans: a randomised, double-blinded, placebo-controlled, crossover study.

2017-09-2565 citations